Recombinant SARS-CoV Spike S1 Subunit Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10685-CV

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10685-CV-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

AAP41037.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all Spike S1 Subunit Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived sars-cov Spike S1 Subunit protein
SARS-CoV Spike S1 Subunit
(Ser14-Leu666)
Accession # AAP41037.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser14

Predicted Molecular Mass

99 kDa

SDS-PAGE

117-131 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).

Scientific Data Images for Recombinant SARS-CoV Spike S1 Subunit Fc Chimera Protein, CF

Recombinant SARS-CoV Spike S1 Subunit Fc Chimera Protein Binding Activity.

Recombinant SARS-CoV Spike S1 Subunit Fc Chimera (Catalog # 10685-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.

Recombinant SARS-CoV Spike S1 Subunit Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant SARS-CoV Spike S1 Subunit Fc Chimera (Catalog # 10685-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 117-131 kDa and 235- 265 kDa, respectively.

Formulation, Preparation and Storage

10685-CV
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Spike S1 Subunit

SARS-CoV was discovered in association with cases of severe acute respiratory syndrome (SARS) that infected more than 8,000 persons with over 900 fatalities worldwide in 2002-2003 (1). It belongs to a family of viruses known as coronaviruses that also include MERS and SARS-Cov2 that causes the global pandemic coronavirus disease 2019 (Covid-19). Coronavirus is commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV S Protein is a type-I trimerized membrane glycoprotein that mediates membrane fusion and viral entry. As with most coronaviruses, proteolytic cleavage of the S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (2-4). A metallopeptidase, angiotensin-converting enzyme 2 (ACE-2), has been identified as a functional receptor for SARS-CoV through interaction with a receptor binding domain (RBD) located at the C-terminus of S1 subunit (5, 6). Based on amino acid (aa) sequence homology, the S1 subunit of SARS-Cov shares 65% and 24% homology with S1 subunit of SARS-CoV2 and MERS, respectively. Before binding to the ACE-2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains in the trimeric structure is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy (7). Antibodies to S protein especially the S1 subunit of SARS-CoV have been shown to inhibit interaction with the ACE-2 receptor, confirming S1 subunit as an attractive target for vaccinations or antiviral therapy (8).

References

  1. Rota, P.A. et al. (2003) Science 300:1394.
  2. Bosch, B.J. et al. (2003). J. Virol. 77:8801.
  3. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. USA 106:5871.
  4. Millet, J.K. and G. R. Whittaker (2015) Virus Res. 202:120.
  5. Li, W. et al. (2003) Nature 426:450.
  6. Wong, S.K. et al. (2004) J. Biol. Chem. 279:3197.
  7. Ortega, J.T. et al. (2020) EXCLI J. 19:410.
  8. Du, L. el al. (2009) Nat. Rev. Microbiol. 7:226.

Long Name

Spike Protein, S1 Subunit

Alternate Names

SARS-CoV-2

UniProt

AAP41037.1

Additional Spike S1 Subunit Products

Product Documents for Recombinant SARS-CoV Spike S1 Subunit Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant SARS-CoV Spike S1 Subunit Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.